Definition of CD4 immunosignatures associated with MTB

Frontiers in Immunology

Volumn 5, Issue MAR, 2014, Pages

  Lindestam Arlehamn, Cecilia S ^a   Sette, Alessandro ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

Epitope; Genome wide; HLA; T cells; Tuberculosis

Indexed keywords

BCG VACCINE; CD1 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CXCR3; EPITOPE; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; HLA DQ ANTIGEN; HLA DR4 ANTIGEN; HLA DRB1 ANTIGEN; HLA DRB3 ANTIGEN; HLA DRB4 ANTIGEN; HLA DRB5 ANTIGEN; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

BCG VACCINATION; BIOINFORMATICS; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; MYCOBACTERIUM TUBERCULOSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; TUBERCULOSIS;

EID: 84897952351     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00124     Document Type: Review

References (91)

1. WHO. Global Tuberculosis Report 2012. Geneva: World Health Organization (2012).
2. Comstock GW. Epidemiology of tuberculosis. Am Rev Respir Dis (1982) 125:8-15.
3. Kaufmann SH. Is the development of a new tuberculosis vaccine possible? Nat Med (2000) 6:955-60. doi: 10.1038/79631
4. Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest (2009) 136:420-5. doi:10.1378/chest.08-2427
5. Boom WH. The role of T-cell subsets in Mycobacterium tuberculosis infection. Infect Agents Dis (1996) 5:73-81.
6. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol (2001) 19:93-129. doi:10.1146/annurev.immunol.19.1.93
7. Kaufmann SHE. How can immunology contribute to the control of tuberculosis? Nat Rev Immunol (2001) 1:20-30. doi:10.1038/35095558
8. Jung Y-J, Ryan L, Lacourse R, North RJ. Properties and protective value of the secondary versus primary T helper type 1 response to airborne Mycobacterium tuberculosis infection in mice. J Exp Med (2005) 201:1915-24. doi:10.1084/jem.20050265
9. Barnes PF, Bloch AB, Davidson PT, Snider DE Jr. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med (1991) 324:1644-50. doi:10.1056/NEJM199106063242307
10. Hopewell PC. Impact of human immunodeficiency virus infection on the epidemiology, clinical features, management, and control of tuberculosis. Clin Infect Dis (1992) 15:540-7. doi:10.1093/clind/15.3.540
11. Raviglione MC, Snider DE Jr, Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA (1995) 273:220-6. doi:10.1001/jama.1995.03520270054031
12. Del Prete GF, De Carli M, Mastromauro C, Biagiotti R, Macchia D, Falagiani P, et al. Purified protein derivative of Mycobacterium tuberculosis and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production. J Clin Invest (1991) 88:346-50. doi:10.1172/JCI115300
13. Newport MJ, Huxley CM, Huston S, Hawrylowicz CM, Oostra BA, Williamson R, et al. A Mutation in the interferon-γ-receptor gene and susceptibility to mycobacterial infection. N Engl J Med (1996) 335:1941-9. doi:10.1056/NEJM199612263352602
14. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med (2001) 345:1098-104. doi:10.1056/NEJMoa011110
15. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (2011) 50:124-31. doi:10.1093/rheumatology/keq242
16. van Crevel R, Karyadi E, Preyers F, Leenders M, Kullberg BJ, Nelwan H, et al. Increased production of interleukin 4 by CD4+ and CD8+ T cells from patients with tuberculosis is related to the presence of pulmonary cavities. J Infect Dis (2000) 181:1194-7. doi:10.1086/315325
17. Morosini M, Meloni F, Marone Bianco A, Paschetto E, Uccelli M, Pozzi E, et al. The assessment of IFN-gamma and its regulatory cytokines in the plasma and bronchoalveolar lavage fluid of patients with active pulmonary tuberculosis. Int J Tuberc Lung Dis (2003) 7:994-1000.
18. Ordway DJ, Costa L, Martins M, Silveira H, Amaral L, Arroz MJ, et al. Increased interleukin-4 production by CD8 and gammadelta T cells in health-care workers is associated with the subsequent development of active tuberculosis. J Infect Dis (2004) 190:756-66. doi:10.1086/422532
19. Harari A, Vallelian F, Meylan PR, Pantaleo G. Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol (2005) 174:1037-45.
20. Beveridge NE, Price DA, Casazza JP, Pathan AA, Sander CR, Asher TE, et al. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol (2007) 37:3089-100. doi:10.1002/eji.200737504
21. Day CL, Mkhwanazi N, Reddy S, Mncube Z, van der Stok M, Klenerman P, et al. Detection of polyfunctional Mycobacterium tuberculosis-specific T cells and association with viral load in HIV-1-infected persons. J Infect Dis (2008) 197:990-9. doi:10.1086/529048
22. Sutherland JS, Adetifa IM, Hill PC, Adegbola RA, Ota MOC. Pattern and diversity of cytokine production differentiates between Mycobacterium tuberculosis infection and disease. Eur J Immunol (2009) 39:723-9. doi:10.1002/eji.200838693
23. Scriba TJ, Tameris M, Mansoor N, Smit E, Van Der Merwe L, Isaacs F, et al. Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol (2010) 40:279-90. doi:10.1002/eji.200939754
24. Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol (2007) 8:639-46. doi:10.1038/ni1467
25. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cilley GE, et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol (2007) 8:369-77. doi:10.1038/ni1449
26. Scriba TJ, Kalsdorf B, Abrahams D-A, Isaacs F, Hofmeister J, Black G, et al. Distinct, specific IL-17-and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response. J Immunol (2008) 180:1962-70.
27. Basile JI, Geffner LJ, Romero MM, Balboa L, Sabio YGC, Ritacco V, et al. Outbreaks of Mycobacterium tuberculosis MDR strains induce high IL-17 T-cell response in patients with MDR tuberculosis that is closely associated with high antigen load. J Infect Dis (2011) 204:1054-64. doi:10.1093/infdis/jir460
28. Jurado JO, Pasquinelli V, Alvarez IB, Peña D, Rovetta AI, Tateosian NL, et al. IL-17 and IFN-γ expression in lymphocytes from patients with active tuberculosis correlates with the severity of the disease. J Leukoc Biol (2012) 91:991-1002. doi:10.1189/jlb.1211619
29. Redford PS, Murray PJ, O'Garra A. The role of IL-10 in immune regulation during M. tuberculosis infection. Mucosal Immunol (2011) 4:261-70. doi:10.1038/mi.2011.7
30. Verbon A, Juffermans N, Van Deventer SJ, Speelman P, Van Deutekom H, Van Der Poll T. Serum concentrations of cytokines in patients with active tuberculosis (TB) and after treatment. Clin Exp Immunol (1999) 115:110-3. doi:10.1046/j.1365-2249.1999.00783.x
31. Sette A, Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and-B polymorphism. Immunogenetics (1999) 50:201-12. doi:10.1007/s002510050594
32. Greenbaum J, Sidney J, Chung J, Brander C, Peters B, Sette A. Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes. Immunogenetics (2011) 63:325-35. doi:10.1007/s00251-011-0513-0
33. McKinney DM, Southwood S, Hinz D, Oseroff C, Arlehamn CS, Schulten V, et al. A strategy to determine HLA class II restriction broadly covering the DR, DP, and DQ allelic variants most commonly expressed in the general population. Immunogenetics (2013) 65:357-70. doi:10.1007/s00251-013-0684-y
34. Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity (1994) 1:751-61. doi:10.1016/S1074-7613(94)80017-0
35. Southwood S, Sidney J, Kondo A, Del Guercio M-F, Appella E, Hoffman S, et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol (1998) 160:3363-73.
36. O'Sullivan D, Arrhenius T, Sidney J, Del Guercio MF, Albertson M, Wall M, et al. On the interaction of promiscuous antigenic peptides with different DR alleles. Identification of common structural motifs. J Immunol (1991) 147:2663-9.
37. Castelli FA, Buhot C, Sanson A, Zarour H, Pouvelle-Moratille S, Nonn C, et al. HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity. J Immunol (2002) 169:6928-34.
38. Berretta F, Butler RH, Diaz G, Sanarico N, Arroyo J, Fraziano M, et al. Detailed analysis of the effects of Glu/Lys beta69 human leukocyte antigen-DP polymorphism on peptide-binding specificity. Tissue Antigens (2003) 62:459-71. doi:10.1046/j.1399-0039.2003.00131.x
39. Sidney J, Steen A, Moore C, Ngo S, Chung J, Peters B, et al. Five HLA-DP molecules frequently expressed in the worldwide human population share a common HLA supertypic binding specificity. J Immunol (2010) 184:2492-503. doi:10.4049/jimmunol.0903655
40. Sidney J, Del Guercio MF, Southwood S, Sette A. The HLA molecules DQA1*0501/B1*0201 and DQA1*0301/B1*0302 share an extensive overlap in peptide binding specificity. J Immunol (2002) 169:5098-108.
41. Sidney J, Steen A, Moore C, Ngo S, Chung J, Peters B, et al. Divergent motifs but overlapping binding repertoires of six HLA-DQ molecules frequently expressed in the worldwide human population. J Immunol (2010) 185:4189-98. doi:10.4049/jimmunol.1001006
42. Chelvanayagam G. A roadmap for HLA-DR peptide binding specificities. Hum Immunol (1997) 58:61-9.
43. Ou D, Mitchell LA, Tingle AJ. A new categorization of HLA DR alleles on a functional basis. Hum Immunol (1998) 59:665-76. doi:10.1016/S0198-8859(98)00067-6
44. Doytchinova IA, Flower DR. In silico identification of supertypes for class II MHCs. J Immunol (2005) 174:7085-95.
45. Nielsen M, Lund O, Buus S, Lundegaard C. MHC class II epitope predictive algorithms. Immunology (2010) 130:319-28. doi:10.1111/j.1365-2567.2010.03268.x
46. Lamonaca V, Missale G, Urbani S, Pilli M, Boni C, Mori C, et al. Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: implications for vaccine development. Hepatology (1999) 30:1088-98. doi:10.1002/hep.510300435
47. Doolan DL, Southwood S, Chesnut R, Appella E, Gomez E, Richards A, et al. HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles. J Immunol (2000) 165:1123-37.
48. Wilson CC, Palmer B, Southwood S, Sidney J, Higashimoto Y, Appella E, et al. Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes. J Virol (2001) 75:4195-207. doi:10.1128/JVI.75.9.4195-4207.2001
49. Tangri S, Mothe BR, Eisenbraun J, Sidney J, Southwood S, Briggs K, et al. Rationally engineered therapeutic proteins with reduced immunogenicity. J Immunol (2005) 174:3187-96.
50. Lindestam Arlehamn CS, Sidney J, Henderson R, Greenbaum JA, James EA, Moutaftsi M, et al. Dissecting mechanisms of immunodominance to the common tuberculosis antigens ESAT-6, CFP10, Rv2031c (hspX), Rv2654c (TB7.7), and Rv1038c (EsxJ). J Immunol (2012) 188:5020-31. doi:10.4049/jimmunol.1103556
51. Assarsson E, Bui H-H, Sidney J, Zhang Q, Glenn J, Oseroff C, et al. Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans. J Virol (2008) 82:12241-51. doi:10.1128/JVI.01563-08
52. Oseroff C, Sidney J, Kotturi MF, Kolla R, Alam R, Broide DH, et al. Molecular determinants of T cell epitope recognition to the common Timothy grass allergen. J Immunol (2010) 185:943-55. doi:10.4049/jimmunol.1000405
53. Oseroff C, Sidney J, Tripple V, Grey H, Wood R, Broide DH, et al. Analysis of T cell responses to the major allergens from German cockroach: epitope specificity and relationship to IgE production. J Immunol (2012) 189:679-88. doi:10.4049/jimmunol.1200694
54. Oseroff C, Sidney J, Vita R, Tripple V, Mckinney DM, Southwood S, et al. T cell responses to known allergen proteins are differently polarized and account for a variable fraction of total response to allergen extracts. J Immunol (2012) 189:1800-11. doi:10.4049/jimmunol.1200850
55. Wang P, Sidney J, Kim Y, Sette A, Lund O, Nielsen M, et al. Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics (2010) 11:568. doi:10.1186/1471-2105-11-568
56. Cole S, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature (1998) 393:537-544. doi:10.1038/31159
57. Lindestam Arlehamn CS, Gerasimova A, Mele F, Henderson R, Swann J, Greenbaum JA, et al. Memory T cells in latent Mycobacterium tuberculosis infection are directed against three antigenic islands and largely contained in a CXCR3+CCR6+ Th1 subset. PLoS Pathog (2013) 9:e1003130. doi:10.1371/journal.ppat.1003130
58. Gosselin A, Monteiro P, Chomont N, Diaz-Griffero F, Said EA, Fonseca S, et al. Peripheral blood CCR4+CCR6+ and CXCR3+CCR6+CD4+ T cells are highly permissive to HIV-1 infection. J Immunol (2010) 184:1604-16. doi:10.4049/jimmunol.0903058
59. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet (2013) 381:1021-8. doi:10.1016/S0140-6736(13)60177-4
60. Lew JM, Kapopoulou A, Jones LM, Cole ST. TubercuList-10 years after. Tuberculosis (2011) 91:1-7. doi:10.1016/j.tube.2010.09.008
61. Andersen P. The T cell response to secreted antigens of Mycobacterium tuberculosis. Immunobiology (1994) 191:537-47. doi:10.1016/S0171-2985(11)80460-2
62. Boesen H, Jensen B, Wilcke T, Andersen P. Human T-cell responses to secreted antigen fractions of Mycobacterium tuberculosis. Infect Immun (1995) 63:1491-7.
63. Blythe M, Zhang Q, Vaughan K, De Castro R, Salimi N, Bui H-H, et al. An analysis of the epitope knowledge related to mycobacteria. Immunome Res (2007) 3:10. doi:10.1186/1745-7580-3-10
64. Gey Van Pittius N, Gamieldien J, Hide W, Brown G, Siezen R, Beyers A. The ESAT-6 gene cluster of Mycobacterium tuberculosis and other high G+C Gram-positive bacteria. Genome Biol (2001) 2:research0044.0041-research0044.0018. doi:10.1186/gb-2001-2-10-research0044
65. Geiger R, Duhen T, Lanzavecchia A, Sallusto F. Human naive and memory CD4+ T cell repertoires specific for naturally processed antigens analyzed using libraries of amplified T cells. J Exp Med (2009) 206:1525-34. doi:10.1084/jem.20090504
66. Barnes E, Ward SM, Kasprowicz VO, Dusheiko G, Klenerman P, Lucas M. Ultra-sensitive class I tetramer analysis reveals previously undetectable populations of antiviral CD8+ T cells. Eur J Immunol (2004) 34:1570-7. doi:10.1002/eji.200424898
67. Zielinski CE, Corti D, Mele F, Pinto D, Lanzavecchia A, Sallusto F. Dissecting the human immunologic memory for pathogens. Immunol Rev (2011) 240:40-51. doi:10.1111/j.1600-065X.2010.01000.x
68. Sidney J, Southwood S, Moore C, Oseroff C, Pinilla C, Grey HM, et al. Measurement of MHC/peptide interactions by gel filtration or monoclonal antibody capture. Curr Protoc Immunol (2013) Chapter 18:Unit18.13. doi:10.1002/0471142735.im1803s100
69. Young DB, Gideon HP, Wilkinson RJ. Eliminating latent tuberculosis. Trends Microbiol (2009) 17:183-8. doi:10.1016/j.tim.2009.02.005
70. Wilkinson RJ, De Smet KA, Haslov K, Pasvol G, Singh M, Svarcova I, et al. Human T-and B-cell reactivity to the 16kDa alpha-crystallin protein of Mycobacterium tuberculosis. Scand J Immunol (1998) 48:403-9. doi:10.1046/j.1365-3083.1998.00420.x
71. Leyten EMS, Lin MY, Franken KLMC, Friggen AH, Prins C, Van Meijgaarden KE, et al. Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. Microbes Infect (2006) 8:2052-60. doi:10.1016/j.micinf.2006.03.018
72. Wayne LG, Sohaskey CD. Nonreplicating persistence of Mycobacterium tuberculosis. Annu Rev Microbiol (2001) 55:139-63. doi:10.1146/annurev.micro.55.1.139
73. Sherman DR, Voskuil M, Schnappinger D, Liao R, Harrell MI, Schoolnik GK. Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha-crystallin. Proc Natl Acad Sci U S A (2001) 98:7534-9. doi:10.1073/pnas.121172498
74. Roberts DM, Liao RP, Wisedchaisri G, Hol WG, Sherman DR. Two sensor kinases contribute to the hypoxic response of Mycobacterium tuberculosis. J Biol Chem (2004) 279:23082-7. doi:10.1074/jbc.M401230200
75. Demissie A, Leyten EMS, Abebe M, Wassie L, Aseffa A, Abate G, et al. Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clin Vaccine Immunol (2006) 13:179-86. doi:10.1128/CVI.13.2.179-186.2006
76. Geluk A, Lin MY, Van Meijgaarden KE, Leyten EMS, Franken KLMC, Ottenhoff THM, et al. T-cell recognition of the HspX protein of Mycobacterium tuberculosis correlates with latent M. tuberculosis infection but not with M. bovis BCG vaccination. Infect Immun (2007) 75:2914-21. doi:10.1128/IAI.01990-06
77. Roupie V, Romano M, Zhang L, Korf H, Lin MY, Franken KLMC, et al. Immunogenicity of eight dormancy regulon-encoded proteins of Mycobacterium tuberculosis in DNA-vaccinated and tuberculosis-infected mice. Infect Immun (2007) 75:941-9. doi:10.1128/IAI.01137-06
78. Schuck SD, Mueller H, Kunitz F, Neher A, Hoffmann H, Franken KLCM, et al. Identification of T-cell antigens specific for latent Mycobacterium Tuberculosis infection. PLoS One (2009) 4:e5590. doi:10.1371/journal.pone.0005590
79. Commandeur S, Van Meijgaarden KE, Lin MY, Franken KLMC, Friggen AH, Drijfhout JW, et al. Identification of human T-cell responses to Mycobacterium tuberculosis resuscitation promoting factors in long-term latently infected individuals. Clin Vaccine Immunol (2011) 18:676-83. doi:10.1128/CVI.00492-10
80. Kell DB, Young M. Bacterial dormancy and culturability: the role of autocrine growth factors. Curr Opin Microbiol (2000) 3:238-43. doi:10.1016/S1369-5274(00)00082-5
81. Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, et al. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics (1995) 96:29-35.
82. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet (1995) 346:1339-45. doi:10.1016/S0140-6736(95)92348-9
83. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet (2006) 367:1173-80. doi:10.1016/S0140-6736(06)68507-3
84. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med (2004) 10:1240-4. doi:10.1038/nm1128
85. Scriba TJ, Tameris M, Mansoor N, Smit E, Van Der Merwe L, Mauff K, et al. Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. J Infect Dis (2011) 203:1832-43. doi:10.1093/infdis/jir195
86. D'Souza S, Rosseels V, Romano M, Tanghe A, Denis O, Jurion F, et al. Mapping of murine Th1 helper T-cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis. Infect Immun (2003) 71:483-93. doi:10.1128/IAI.71.1.483-493.2003
87. Ravn P, Boesen H, Pedersen BK, Andersen P. Human T cell responses induced by vaccination with Mycobacterium bovis bacillus Calmette-Guerin. J Immunol (1997) 158:1949-55.
88. Kagina BM, Abel B, Scriba TJ, Hughes EJ, Keyser A, Soares A, et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am J Respir Crit Care Med (2010) 182:1073-9. doi:10.1164/rccm.201003-0334OC
89. Hanekom WA. The immune response to BCG vaccination of newborns. Ann N Y Acad Sci (2005) 1062:69-78. doi:10.1196/annals.1358.010
90. Orme IM. The Achilles heel of BCG. Tuberculosis (2010) 90:329-32. doi:10.1016/j.tube.2010.06.002
91. Abebe F. Is interferon-gamma the right marker for bacille Calmette-Guérin-induced immune protection? The missing link in our understanding of tuberculosis immunology. Clin Exp Immunol (2012) 169:213-9. doi:10.1111/j.1365-2249.2012.04614.x